SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-040473
Filing Date
2019-07-02
Accepted
2019-07-02 17:24:24
Documents
2
Period of Report
2019-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2259
2 POA DOCUMENT poa.txt EX-24.3_863445 3972
  Complete submission text file 0001209191-19-040473.txt   7910
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Issuer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O STEADYMED THERAPEUTICS, INC. 2410 CAMINO RAMON SAN RAMON CA 94583
Business Address
Nassif David W. (Reporting) CIK: 0001636975 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37418 | Film No.: 19939036